Jul 7, 2026 07:50AM
May 6, 2026 08:31AM
May 4, 2026 08:30AM
Mar 27, 2026 06:46AM
Mar 12, 2026 08:03AM
Feb 11, 2026 08:31AM
Feb 5, 2026 08:31AM Atossa maintains eligibility for priority review voucher after program renewal
Jan 6, 2026 08:15AM
Dec 11, 2025 08:02AM
Dec 9, 2025 08:01AM
Dec 8, 2025 04:46AM
Dec 5, 2025 06:46AM
Dec 4, 2025 08:01AM
Dec 2, 2025 08:01AM Insilico Medicine and Atossa publish study on brain cancer treatment
Nov 17, 2025 09:09AM
Nov 12, 2025 04:23PM
Oct 14, 2025 07:53AM
Oct 7, 2025 06:47AM
Oct 6, 2025 08:04AM
Oct 1, 2025 08:32AM
Sep 9, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on Atossa Genetics (ATOS)
Sep 8, 2025 08:30AM
Aug 29, 2025 09:00AM
Aug 12, 2025 09:46AM
Aug 1, 2025 09:00AM
Jun 6, 2025 05:21AM
Jun 5, 2025 08:39AM
May 20, 2025 09:00AM Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22
May 13, 2025 05:31PM
May 2, 2025 09:00AM
Apr 30, 2025 08:45AM
Apr 29, 2025 08:47AM
Apr 22, 2025 08:45AM
Mar 26, 2025 06:52AM
Mar 11, 2025 08:15AM Atossa Therapeutics (ATOS) Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
Jan 30, 2025 08:17AM
Jan 23, 2025 08:15AM
Dec 11, 2024 08:15AM
Nov 13, 2024 06:54AM
Nov 5, 2024 08:05AM
Nov 4, 2024 06:30AM
Oct 31, 2024 08:15AM Atossa Therapeutics (ATOS) Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer
Sep 10, 2024 08:30AM
Aug 28, 2024 08:31AM
Aug 21, 2024 11:37AM
Aug 21, 2024 08:37AM
Aug 12, 2024 05:06PM
Jul 2, 2024 04:15PM
Jul 1, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on Atossa Genetics (ATOS)
Jun 28, 2024 08:32AM

430,616 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All